Immuneering Corporation (NASDAQ:IMRX) Receives $13.00 Consensus Price Target from Analysts

Shares of Immuneering Corporation (NASDAQ:IMRX) have been given an average rating of “Moderate Buy” by the five research firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $13.00.

Several equities research analysts have issued reports on IMRX shares. Chardan Capital restated a “buy” rating and issued a $13.00 price target on shares of Immuneering in a report on Thursday, August 14th. Mizuho increased their price target on Immuneering from $8.00 to $10.00 and gave the stock an “outperform” rating in a report on Wednesday, June 18th. Finally, Needham & Company LLC restated a “buy” rating and issued a $8.00 price target on shares of Immuneering in a report on Tuesday, August 26th.

Immuneering Trading Up 15.5%

NASDAQ IMRX opened at $8.14 on Thursday. The stock has a 50-day simple moving average of $4.37 and a 200 day simple moving average of $2.63. The company has a market capitalization of $338.38 million, a PE ratio of -4.31 and a beta of 0.43. Immuneering has a 12 month low of $1.10 and a 12 month high of $9.37.

Immuneering (NASDAQ:IMRX) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($0.40) EPS for the quarter, meeting analysts’ consensus estimates of ($0.40). As a group, sell-side analysts predict that Immuneering will post -1.86 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Benjamin J. Zeskind acquired 21,000 shares of Immuneering stock in a transaction dated Wednesday, June 18th. The stock was bought at an average cost of $2.39 per share, with a total value of $50,190.00. Following the completion of the transaction, the chief executive officer directly owned 2,302,852 shares of the company’s stock, valued at approximately $5,503,816.28. This represents a 0.92% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Thomas J. Schall acquired 9,500 shares of Immuneering stock in a transaction dated Friday, June 27th. The shares were purchased at an average cost of $3.66 per share, with a total value of $34,770.00. Following the completion of the transaction, the director directly owned 52,885 shares of the company’s stock, valued at $193,559.10. This trade represents a 21.90% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 127,507 shares of company stock worth $334,318 over the last ninety days. 22.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of IMRX. Tang Capital Management LLC acquired a new position in shares of Immuneering during the fourth quarter worth about $27,000. Jane Street Group LLC acquired a new position in shares of Immuneering during the first quarter worth about $32,000. Kingsview Wealth Management LLC acquired a new position in shares of Immuneering during the second quarter worth about $47,000. Marshall Wace LLP acquired a new position in shares of Immuneering during the fourth quarter worth about $47,000. Finally, First Manhattan CO. LLC. acquired a new position in shares of Immuneering during the fourth quarter worth about $71,000. 67.65% of the stock is owned by institutional investors and hedge funds.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.